Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Work In Process (2016 - 2026)

Ocular Therapeutix has reported Work In Process over the past 13 years, most recently at $1.2 million for Q1 2026.

  • For Q1 2026, Work In Process fell 31.19% year-over-year to $1.2 million; the TTM value through Mar 2026 reached $1.2 million, down 31.19%, while the annual FY2025 figure was $1.7 million, 15.58% up from the prior year.
  • Work In Process for Q1 2026 was $1.2 million at Ocular Therapeutix, down from $1.7 million in the prior quarter.
  • Over five years, Work In Process peaked at $1.8 million in Q1 2025 and troughed at $567000.0 in Q1 2022.
  • A 5-year average of $1.1 million and a median of $1.0 million in 2023 define the central range for Work In Process.
  • Biggest five-year swings in Work In Process: skyrocketed 97.27% in 2025 and later tumbled 31.19% in 2026.
  • Year by year, Work In Process stood at $899000.0 in 2022, then increased by 12.57% to $1.0 million in 2023, then skyrocketed by 47.13% to $1.5 million in 2024, then grew by 15.58% to $1.7 million in 2025, then decreased by 27.83% to $1.2 million in 2026.
  • Business Quant data shows Work In Process for OCUL at $1.2 million in Q1 2026, $1.7 million in Q4 2025, and $1.4 million in Q3 2025.